Looking for Pharmaceutical Excipients offered by Actylis? Find 6-[6-[6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-2-carboxy-4-hydroxy-5-sulfooxyoxan-3-yl]oxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid to address your drug delivery challenges on PharmaCompass.

6-[6-[6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-2-carboxy-4-hydroxy-5-sulfooxyoxan-3-yl]oxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

35 API Suppliers, 14 USDMF, 3 CEP/COS, 5 KDMF, 8 NDC API, 20 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

56 Drugs in Development

56 Drugs in Development

INTERMEDIATES

2 Intermediate Suppliers

2 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

408 FDF Dossiers, 62 FDA Orange Book, 172 Europe, 44 Canada, 40 Australia, 18 South Africa, 72 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;SUBCUTANEOUS - 100MG/ML (100MG/ML), INJECTABLE;SUBCUTANEOUS - 120MG/0.8ML (150MG/ML), INJECTABLE;SUBCUTANEOUS - 150MG/ML (150MG/ML), INJECTABLE;INTRAVENOUS, SUBCUTANEOUS - 300MG/3ML (100MG/ML), INJECTABLE;SUBCUTANEOUS - 30MG/0.3ML (100MG/ML), INJECTABLE;SUBCUTANEOUS - 40MG/0.4ML (100MG/ML), INJECTABLE;SUBCUTANEOUS - 60MG/0.6ML (100MG/ML), INJECTABLE;SUBCUTANEOUS - 80MG/0.8ML (100MG/ML), INJECTABLE;SUBCUTANEOUS - 90MG/0.6ML (150MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**